In a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Biolase (BIOL – Research Report), with a price target of $2.00. The company's shares closed last Thursday at $0.40, close to its 52-week low of $0.27. According to TipRanks.com, Bauser is a 2-star analyst with an average return of 0.3% and a 45.5% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Chembio Diagnostics, Semler Scientific, and Motus Gi Holdings. Biolase has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.
https://www.tipranks.com/news/blurbs/colliers-securities-thinks-biolases-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral